Stockscreener 앱 받기
0.7084
0.99%
-0.0071
전일 마감가:
$0.7155
열려 있는:
$0.7299
하루 거래량:
145.32K
Relative Volume:
0.27
시가총액:
$32.71M
수익:
-
순이익/손실:
$-81.22M
주가수익비율:
-0.2393
EPS:
-2.96
순현금흐름:
$-74.41M
1주 성능:
-14.62%
1개월 성능:
-26.97%
6개월 성능:
-26.21%
1년 성능:
+6.53%
1일 변동 폭
$0.684
$0.7299
1주일 범위
$0.67
$0.8547
52주 변동 폭
$0.5001
$1.93
Xilio Therapeutics Inc Stock (XLO) Company Profile
명칭
Xilio Therapeutics Inc
전화
617-833-1027
주소
828 WINTER STREET, WALTHAM
XLO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.7084 | 32.71M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.19 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.84 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
662.88 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.25 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.41 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-12-21 | 개시 | Chardan Capital Markets | Buy |
| 2022-01-10 | 개시 | H.C. Wainwright | Buy |
| 2021-11-16 | 개시 | Cowen | Outperform |
| 2021-11-16 | 개시 | Guggenheim | Buy |
| 2021-11-16 | 개시 | Morgan Stanley | Overweight |
| 2021-11-16 | 개시 | Raymond James | Outperform |
모두보기
Xilio Therapeutics Inc 주식(XLO)의 최신 뉴스
Xilio shares tumble after mixed vilastobart data - The Pharma Letter
Vilastobart set apart? Xilio phase II combo performs in CRC - BioWorld Online
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer - Marketscreener.com
Xilio Therapeutics Advances with Phase 2 Trial Data - TipRanks
Xilio Therapeutics Announces Initial Phase 2 Data for - GlobeNewswire
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated - The Bakersfield Californian
Xilio Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(4) - Marketscreener.com
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Xilio Therapeutics Awards 60,000-Share Stock Option Grant to New Employee at $0.955 - StockTitan
Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Rises By 221.7% - Defense World
Geode Capital Management LLC Grows Position in Xilio Therapeutics, Inc. (NASDAQ:XLO) - Defense World
Xilio Therapeutics Inc [XLO] stock for 6,841 USD was sold by Frankenfield Christopher James - Knox Daily
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 31.9% in December - Defense World
Xilio Therapeutics Enters into Additional Private Placement with Gilead; Issues Securities at $25 Million Aggregate Investment - Defense World
Gilead Sciences acquires $1.83 million in Xilio Therapeutics stock - Investing.com India
Gilead Sciences acquires $1.83 million in Xilio Therapeutics stock By Investing.com - Investing.com Australia
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated - The Bakersfield Californian
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI - GlobeNewswire
Xilio Therapeutics Hires Caroline Hensley as Chief Legal Officer - Bloomberg Law
Biotech Biz Xilio Therapeutics Appoints Chief Legal Officer - Law360
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer - The Bakersfield Californian
Xilio Therapeutics Strengthens Leadership Team, Appoints Seres Therapeutics Veteran as Chief Legal Officer - StockTitan
Xilio Therapeutics, Inc. Appoints Caroline Hensley as chief legal officer - Marketscreener.com
Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Increases By 317.4% - Defense World
After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright - MSN
Here's Why We're Not Too Worried About Xilio Therapeutics' (NASDAQ:XLO) Cash Burn Situation - Yahoo Finance
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 89.4% in November - Defense World
Raymond James Cuts Xilio Therapeutics (NASDAQ:XLO) Price Target to $4.00 - Defense World
Xilio to present new cancer treatment data at SITC By Investing.com - Investing.com Australia
Xilio Therapeutics Reports Q3 2024 Progress and Financials - TipRanks
Xilio Therapeutics Inc. (XLO) Quarterly 10-Q Report - Quartzy
Xilio to present new cancer treatment data at SITC - Investing.com
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results - citybiz
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors - GlobeNewswire
Xilio's Cancer Drug Shows Promise: Liver Metastasis Resolution in Clinical Trial | XLO Stock News - StockTitan
Xilio Therapeutics to Present Initial Phase 1C Dose - GlobeNewswire
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewswire Inc.
Companies Like Xilio Therapeutics (NASDAQ:XLO) Are In A Position To Invest In Growth - Simply Wall St
Xilio Therapeutics Announces Upcoming Poster Presentation - GlobeNewswire
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of - The Bakersfield Californian
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - StockTitan
Xilio Therapeutics Inc (XLO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.45%
5.38%
자본화:
|
볼륨(24시간):